|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvalYear
|
2019
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L04AA45
|
|
gptkbp:brand
|
gptkb:Mayzent
|
|
gptkbp:CASNumber
|
1230487-00-9
|
|
gptkbp:chemicalFormula
|
C29H35F3N2O3
|
|
gptkbp:clinicalTrialPhase
|
Phase III completed
|
|
gptkbp:color
|
white
|
|
gptkbp:contraindication
|
severe hepatic impairment
CYP2C9*3/*3 genotype
|
|
gptkbp:developer
|
gptkb:Novartis
|
|
gptkbp:drugClass
|
immunotherapy
|
|
gptkbp:eliminationHalfLife
|
about 30 hours
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:hasSMILES
|
CC1=CC(=C(C=C1)C2=NC(=CC(=C2)C3=CC=C(C=C3)C(C)(C)O)C(F)(F)F)N4CCOCC4
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
siponimod
|
|
gptkbp:indication
|
gptkb:secondary_progressive_multiple_sclerosis
relapsing forms of multiple sclerosis
|
|
gptkbp:isPatentProtected
|
yes
|
|
gptkbp:KEGGID
|
D10541
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
sphingosine-1-phosphate receptor modulator
|
|
gptkbp:metabolism
|
gptkb:CYP2C9
gptkb:CYP3A4
|
|
gptkbp:molecularWeight
|
516.6 g/mol
|
|
gptkbp:monitors
|
liver function
cardiac function
ophthalmologic exams
|
|
gptkbp:pregnancyCategory
|
Not recommended
|
|
gptkbp:prescriptionRequired
|
https://www.mayzent.com/
|
|
gptkbp:PubChem_CID
|
CHEMBL2103887
25154714
|
|
gptkbp:riskFactor
|
gptkb:macular_edema
infections
liver injury
cardiac effects
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:macular_edema
headache
hypertension
bradycardia
liver enzyme elevation
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:UNII
|
6Z5B6HVF6O
|
|
gptkbp:usedFor
|
multiple sclerosis
|
|
gptkbp:bfsParent
|
gptkb:Mayzent
|
|
gptkbp:bfsLayer
|
6
|